22.626 articles found

Use of PDE7 inhibitors for the treatment of movement disorders

BERGMANN JOHN E, CUTSHALL NEIL S, DEMOPULOS GREGORY A, FLORIO VINCENT A, GEORGE GAITANARIS, PATRICK GRAY, JOHN HOHMANN, RENE ONRUST, HONGKUI ZENG.

· 2010-05-03

Higher-dose glutathione therapy for Parkinson's disease in Japan: is it really safe?

Naito Y, Matsuo K, Kokubo Y, Narita Y, Tomimoto H.

Mov Disord · 2010-05-01

DOI: 10.1002/mds.23022PMID: 20131395

The effect of cueing therapy on single and dual-task gait in a drug naïve population of people with Parkinson's disease in northern Tanzania.

Rochester L, Rafferty D, Dotchin C, Msuya O, Minde V, Walker RW.

Mov Disord · 2010-05-01

DOI: 10.1002/mds.22978PMID: 20175212

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.

Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.

Clin Neuropharmacol · 2010-05-01

DOI: 10.1097/wnf.0b013e3181d47849PMID: 20216409

Effects of dietary factors on levodopa pharmacokinetics.

Fernandez N, Garcia JJ, Diez MJ, Sahagun AM, Díez R, Sierra M.

Expert Opin Drug Metab Toxicol · 2010-05-01

DOI: 10.1517/17425251003674364PMID: 20384552

Dopamine-dependent motor learning: insight into levodopa's long-duration response.

Beeler JA, Cao ZF, Kheirbek MA, Ding Y, Koranda J, Murakami M, Kang UJ, Zhuang X.

Ann Neurol · 2010-05-01

DOI: 10.1002/ana.21947PMID: 20437561

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.

Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL, 228 Study Investigators.

Mov Disord · 2010-05-01

DOI: 10.1002/mds.22890PMID: 20461803

Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward.

Evans AH, Lawrence AD, Cresswell SA, Katzenschlager R, Lees AJ.

Mov Disord · 2010-05-01

DOI: 10.1002/mds.22898PMID: 20461804

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.

Hersh BP, Earl NL, Hauser RA, Stacy M.

Mov Disord · 2010-05-01

DOI: 10.1002/mds.23040PMID: 20461810

Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.

Ries V, Selzer R, Eichhorn T, Oertel WH, Eggert K, German Tolcapone Study Group.

Clin Neuropharmacol · 2010-05-01

DOI: 10.1097/wnf.0b013e3181d99d6fPMID: 20502133

Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.

Cao X, Yasuda T, Uthayathas S, Watts RL, Mouradian MM, Mochizuki H, Papa SM.

J Neurosci · 2010-05-01

DOI: 10.1523/jneurosci.0252-10.2010PMID: 20505100

The treatment of cognitive impairment associated with Parkinson's disease.

Burn DJ.

Brain Pathol · 2010-05-01

DOI: 10.1111/j.1750-3639.2009.00367.xPMID: 20522093